Most Read

The new, oral formulation of CD/LD extended-release capsules, IPX203 features immediate-release granules and extended-release beads. Findings from the pivotal Phase III RISE-PD clinical trial showed that the extended-release

The collaboration will focus on discovering and developing nucleic acid-based immunotherapies for selected oncology targets using Harbour BioMed’s heavy chain only antibody discovery platform (HCAb). HCAb’s technology produces

This approval comes after European Commission gave its approval earlier this month. About 90% of children by the age of two get infected by RSV, which is a

Currently, the company is enrolling a Phase 1 trial analysing ITI-3000, a plasmid DNA (pDNA) vaccine targeting patients with MCC. MCC is a rare but aggressive form of

Under the deal terms, the company will provide funding for clinical development of its next-generation antibody-drug conjugate (ADC), NAV-001. The experimental ADC targets and kills tumour cells which

The double-blind, multicentre, placebo-controlled, randomised, dose-finding Phase II OCEAN(a)-DOSE study was designed for evaluating olpasiran’s tolerability, safety, as well as the optimal dose in atherosclerotic cardiovascular disease (ASCVD)

The new 1,500m2 facility will expand the company’s large-scale viral vectors production capabilities for vaccines and gene therapy. It has been designed to meet the increasing demand for

Brukinsa has been approved to treat relapsed/refractory (R/R) MZL adult patients who have previously received at least one anti-CD20-based therapy. The Bruton’s tyrosine kinase (BTK) small molecule inhibitor,

Under the deal terms, the company obtained an exclusive option for evaluating the regulatory, clinical development and commercialisation plan for CWRU’s intellectual property portfolio for up to 12